Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines

European Journal of Pharmacology

Volumn 632, Issue 1-3, 2010, Pages 7-13

  Lee, Chung Soo ^a   Kim, Yun Jeong ^a   Jang, Eun Ra ^a   Myung, Soon Chul ^b   Kim, Wonyong ^a  

^a Chung Ang University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Akt inhibitor; Apoptosis related protein; Carboplatin; Cell death; Epithelial ovarian carcinoma cell

Indexed keywords

CARBOPLATIN; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE B INHIBITOR; PROTEIN P53;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL SHAPE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL DEATH; CELL LINE, TUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 77349105044     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.004     Document Type: Article

References (36)

1. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93 (2001) 1062-1074
2. Albihn A., Mo H., Yang Y., and Henriksson M. Camptothecin-induced apoptosis is enhanced by Myc and involves PKCδ signaling. Int. J. Cancer 121 (2007) 1821-1829
3. Armstrong J.S. Mitochondria: a target for cancer therapy. Br. J. Pharmacol. 147 (2006) 239-248
4. Barnett S.F., Bilodeau M.T., and Lindsley C.W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem. 5 (2005) 109-125
5. Bianco R., Melisi D., Ciardiello F., and Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer 42 (2006) 290-294
6. Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J. Clin. Oncol. 21 (2003) 149s-167s
7. Boulikas T., and Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol. Rep. 10 (2003) 1663-1682
8. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61 (2001) 3986-3997
9. Cain K., Bratton S.B., and Cohen G.M. The Afaf-1 apoptosome: a large caspase-activating complex. Biochimie 84 (2002) 203-214
10. Camins A., Pallas M., and Silvestre J.S. Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find. Exp. Clin. Pharmacol. 30 (2008) 43-65
11. Cao X., Deng X., and May W.S. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 102 (2003) 2605-2614
12. Chipuk J.E., and Green D.R. Dissecting p53-dependent apoptosis. Cell Death Differ. 13 (2006) 994-1002
13. Gao G., and Dou Q.P. N-terminal cleavage of Bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome c release and apoptotic cell death. J. Cell. Biochem. 80 (2000) 53-72
14. Go R.S., and Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17 (1999) 409-422
15. Goldwasser F., Bae I., Valenti M., Torres K., and Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55 (1995) 2116-2121
16. Graham K., and Olson M.F. The Ras signalling pathway as a target in cancer therapy. Recent Results Cancer Res. 172 (2007) 125-153
17. Guo R.X., Qiao Y.H., Zhou Y., Li L.X., Shi H.R., and Chen K.S. Increased staining for phosphorylated AKT and nuclear factor-κB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int. 58 (2008) 749-756
18. Hoekstra A.V., Ward E.C., Hardt J.L., Lurain J.R., Singh D.K., Buttin B.M., Schink J.C., and Kim J.J. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol. Oncol. 108 (2008) 609-618
19. Högberg T., Glimelius B., and Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 40 (2001) 340-360
20. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19 (2000) 3-10
21. Hu W., and Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4 (2003) 721-729
22. Itoh M., Chiba H., Noutomi T., Takada E., and Mizuguchi J. Cleavage of Bax-α and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncol. 36 (2000) 277-285
23. Kozikowski A.P., Sun H., Brognard J., and Dennis P.A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc. 125 (2003) 1144-1145
24. Makin G.W., Corfe B.M., Griffiths G.J., Thistlethwaite A., Hickman J.A., and Dive C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. EMBO J. 20 (2001) 6306-6315
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
26. Oberhammer F.A., Pavelka M., Sharma S., Tiefenbacher R., Purchio A.F., Bursch W., and Schulte-Hermann R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5408-5412
27. Singh S., Upadhyay A.K., Ajay A.K., and Bhat M.K. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett. 581 (2007) 289-295
28. Smalley K.S., and Eisen T.G. Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int. J. Cancer 98 (2002) 514-522
29. Steelman L.S., Stadelman K.M., Chappell W.H., Horn S., Bäsecke J., Cervello M., Nicoletti F., Libra M., Stivala F., Martelli A.M., and McCubrey J.A. Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 12 (2008) 1139-1165
30. Vecchione F., Fruscio R., Dell'Anna T., Garbi A., Garcia, Parra R., Corso S., and Lissoni A.A. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 17 (2007) 367-372
31. Westfall S.D., and Skinner M.K. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol. Cancer Ther. 4 (2005) 1764-1771
32. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13 (2006) 921-926
33. Wood D.E., and Newcomb E.W. Cleavage of Bax enhances its cell death function. Exp. Cell Res. 256 (2000) 375-382
34. Xia S., Rosen E.M., and Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res. 65 (2005) 5248-5255
35. Yoeli-Lerner M., and Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5 (2006) 603-605
36. Yuan Z.Q., Feldman R.I., Sussman G.E., Coppola D., Nicosia S.V., and Cheng J.Q. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J. Biol. Chem. 278 (2003) 23432-23440